Hasil Pencarian - Bertrand Arnulf

Perbaiki Hasil
  1. 1
    Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study

    Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study oleh Pierre-Edouard Debureaux, Stéphanie Harel, Nathalie Parquet, Virginie Lemiale, Virginie Siguret, Laurie Goubeau, Florence Morin, Bruno Royer, Wendy Cuccuini, Dikelele Elessa, Floriane Theves, Anne C. Brignier, Elie Azoulay, Elie Azoulay, Bertrand Arnulf, Bertrand Arnulf, Alexis Talbot, Alexis Talbot

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Standing postural reaction to visual and proprioceptive stimulation in chronic acquired demyelinating polyneuropathy

    Standing postural reaction to visual and proprioceptive stimulation in chronic acquired demyelinating polyneuropathy oleh Clement P. Provost, Sophie Tasseel-Ponche, Pierre Lozeron, Giulia Piccinini, Victorine Quintaine, Bertrand Arnulf, Nathalie Kubis, Alain P. Yelnik

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma

    Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma oleh Sophia Ascione, Stéphanie Harel, Florent L. Besson, Rakiba Belkhir, Julien Henry, Bruno Royer, Bertrand Arnulf, Xavier Mariette, Raphaèle Seror

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    The Sec61 translocon is a therapeutic vulnerability in multiple myeloma

    The Sec61 translocon is a therapeutic vulnerability in multiple myeloma oleh Antoine Domenger, Caroline Choisy, Ludivine Baron, Véronique Mayau, Emeline Perthame, Ludovic Deriano, Bertrand Arnulf, Jean‐Christophe Bories, Gilles Dadaglio, Caroline Demangel

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases

    Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases oleh Hélène Vergneault, Djaouida Bengoufa, Aline Frazier-Mironer, Isabelle Brocheriou, Samuel Bitoun, Camille Villesuzanne, Alexis Talbot, Stéphanie Harel, Bertrand Arnulf, Bruno Royer

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

    Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma oleh Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Helgi van de Velde, Huaibao Feng, Andrew Cakana, William Deraedt, Philippe Moreau

    Diterbitkan 2012-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo

    The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo oleh Camille Bono, Lionel Karlin, Stephanie Harel, Enguerran Mouly, Sylvaine Labaume, Lionel Galicier, Sébastien Apcher, Hélène Sauvageon, Jean-Paul Fermand, Jean-Christophe Bories, Bertrand Arnulf

    Diterbitkan 2012-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma

    Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma oleh Maxime Fayon, Carolina Martinez-Cingolani, Audrey Abecassis, Nathalie Roders, Elisabeth Nelson, Caroline Choisy, Alexis Talbot, Armand Bensussan, Jean-Paul Fermand, Bertrand Arnulf, Jean-Christophe Bories

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Neutrophilic Urticaria with Systemic Inflammation Associated with Immunoglobulin A Myeloma

    Neutrophilic Urticaria with Systemic Inflammation Associated with Immunoglobulin A Myeloma oleh Héloïse Paugoy, Anne Saussine, Laure Frumholtz, Maxime Battistella, Marie Jachiet, Jacqueline Rivet, Clémence Lepelletier, Lucie Duverger, Martine Bagot, Alexis Talbot, Bertrand Arnulf, Jean-David Bouaziz

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Thromboembolism and bleeding in systemic amyloidosis: a review

    Thromboembolism and bleeding in systemic amyloidosis: a review oleh Martin Nicol, Virginie Siguret, Giuseppe Vergaro, Alberto Aimo, Michele Emdin, Jean Guillaume Dillinger, Mathilde Baudet, Alain Cohen‐Solal, Camille Villesuzanne, Stephanie Harel, Bruno Royer, Bertrand Arnulf, Damien Logeart

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

    Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study oleh Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Grigoriy Rekhtman, Zvenyslava Masliak, Pawel Robak, Dixie-Lee Esseltine, Huaibao Feng, William Deraedt, Helgi van de Velde, Bertrand Arnulf

    Diterbitkan 2015-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients.

    A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients. oleh Séverine Lecourt, Enguerran Mouly, Delphine Freida, Audrey Cras, Raphaël Ceccaldi, Djazia Heraoui, Christine Chomienne, Jean-Pierre Marolleau, Bertrand Arnulf, Raphael Porcher, Catherine Caillaud, Valérie Vanneaux, Nadia Belmatoug, Jérôme Larghero

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study

    Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study oleh Martin Nicol, Giuseppe Vergaro, Thibaud Damy, Mounira Kharoubi, Mathilde Baudet, Elena Sofia Canuti, Alberto Aimo, Vincenzo Castiglione, Michele Emdin, Bruno Royer, Stephanie Harel, Alain Cohen-Solal, Bertrand Arnulf, Damien Logeart

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment

    CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment oleh Audrey Abecassis, Nathalie Roders, Maxime Fayon, Caroline Choisy, Elisabeth Nelson, Stephanie Harel, Bruno Royer, Camille Villesuzanne, Alexis Talbot, David Garrick, Michele Goodhardt, Jean‐Paul Fermand, Mike Burbridge, Bertrand Arnulf, Jean‐Christophe Bories

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study

    Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study oleh Axel André, Lydia Montes, Damien Roos‐Weil, Laurent Frenzel, Marguerite Vignon, Thomas Chalopin, Pierre‐Edouard Debureaux, Alexis Talbot, Agathe Farge, Fabrice Jardin, Karim Belhadj, Bruno Royer, Jean‐Pierre Marolleau, Bertrand Arnulf, Pierre Morel, Stéphanie Harel

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS

    P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL)... oleh Michel Delforge, Krina Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas Marshall, Bertrand Arnulf, Michele Cavo, Ajay Nooka, Salomon Manier, Natalie Callander, Sergio Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa Mckiver, Mark Cook, Paula Rodríguez-Otero

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis

    MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis oleh Anne Lazareth, Xiu-Yi Song, Aurelie Coquin, Stephanie Harel, Lionel Karlin, Karim Belhadj, Damien Roos-Weil, Laurent Frenzel, Jerôme Tamburini, Margaret Macro, Sylvie Chevret, Hervé Avet Loiseau, Stephane Minvielle, Jean Paul Fermand, Jean Soulier, Jean Christophe Bories, Bertrand Arnulf

    Diterbitkan 2015-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    The use of ICU resources in CAR-T cell recipients: a hospital-wide study

    The use of ICU resources in CAR-T cell recipients: a hospital-wide study oleh Sandrine Valade, Michael Darmon, Lara Zafrani, Eric Mariotte, Virginie Lemiale, Swann Bredin, Guillaume Dumas, Nicolas Boissel, Florence Rabian, André Baruchel, Isabelle Madelaine, Jérôme Larghero, Anne Brignier, Etienne Lengliné, Stéphanie Harel, Bertrand Arnulf, Roberta Di Blasi, Catherine Thieblemont, Elie Azoulay

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3

    S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATIO... oleh Mohamad Mohty, Michael H. Tomasson, Bertrand Arnulf, Nizar J Bahlis, Paula Rodríguez-Otero, Joaquín Martinez-Lopez, Cyrille Touzeau, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Salomon Manier, Noopur Raje, Marc S. Raab, Emma Searle, Eric Leip, Sharon T. Sullivan, Akos Czibere, Andrea Viqueira, Alexander Lesokhin

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study

    Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study oleh Pierre-Edouard Debureaux, Nathalie Forgeard, Dikelele Elessa, Stéphanie Harel, Laurent Frenzel, Bruno Royer, Alexis Talbot, Sylvain Choquet, Frederic Davi, Florence Nguyen-Khac, Wendy Cuccuini, Morgane Cheminant, Clotilde Bravetti, Gregory Lazarian, Sophie Kaltenbach, Olivier Hermine, Damien Roos-Weil, Marion Espéli, Karl Balabanian, Bertrand Arnulf

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: